General Information of Drug (ID: DMWMBIV)

Drug Name
CRA1000 Drug Info
Synonyms
CRA-1000; CRA1000; UNII-3899V9A17F; 3899V9A17F; CRA 1000; 226948-11-4; 2-Pyrimidinamine, N-ethyl-4-(4-(3-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-6-methyl-N-(4-(1-methylethyl)-2-(methylthio)phenyl)-; 2-(N-(2-methylthio-4-isopropylphenyl)-N-ethylamino)-4-(4-(3-fluorophenyl)-1,2,3,6-tetrahydropyridin-1-yl)-6-methylpyrimidine; CHEMBL297986; SCHEMBL6171730; GTPL3498; PDSP2_001710; PDSP1_001727
Indication
Disease Entry ICD 11 Status REF
Anxiety disorder 6B00-6B0Z Preclinical [1]
Cross-matching ID
PubChem CID
9849313
CAS Number
CAS 226948-11-4
TTD Drug ID
DMWMBIV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Telavancin DM58VQX Staphylococcus infection 1B5Y Approved [2]
Pexacerfont DMBJ15R Anxiety disorder 6B00-6B0Z Phase 2/3 [3]
SSR125543 DMGJEB8 Anxiety disorder 6B00-6B0Z Phase 2 [4]
ONO-2333Ms DMOT0WR Anxiety disorder 6B00-6B0Z Phase 2 [5]
GSK561679 DMEVARK Alcohol dependence 6C40.2 Phase 2 [6]
Tildacerfont DMAB8LH Congenital adrenal hyperplasia 5A71.01 Phase 2 [7]
GSK586529 DM5E9LX Anxiety disorder 6B00-6B0Z Phase 1 [6]
GW876008 DMAXRBI Irritable bowel syndrome DD91.0 Discontinued in Phase 2 [3]
CP-316,311 DMZ76EM Major depressive disorder 6A70.3 Discontinued in Phase 2 [3]
NBI-37582 DM3JY2N Anxiety disorder 6B00-6B0Z Terminated [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Corticotropin-releasing factor receptor 1 (CRHR1) TT7EFHR CRFR1_HUMAN Antagonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3498).
2 A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
3 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
4 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
5 Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013 Mar 1;128(3):175-86.
6 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
7 Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021 Nov 30;186(1):R1-R14.
8 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.